Thymosin Alpha-1 and Exercise: What to Know About Training While on This Medication

HealthRX.com

No trial data on training while using thymosin alpha-1

Print or save as PDF

Key numbers

  • 1.6 mgItaly's Zadaxin label dose, twice weekly, for immunocompromised people during influenza vaccinationSource: fda.gov, as cited Nov 7, 2026
  • 1.8 to 2.6 hoursHalf-life after a subcutaneous injection, which sets how long the drug stays in the bloodSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 17 million dosesDoses given, per manufacturer-linked authors' reports of marketing experienceSource: fda.gov, as cited Nov 7, 2026
  • FDA status / not approved in the US; no US-approved dose [1]
  • Authorized elsewhere / Italy (influenza vaccine adjuvant), India (chronic hepatitis B), Hong Kong [1]
  • Anti-doping / not named on WADA's 2026 Prohibited List [2]
  • Half-life / about 1.8 to 2.6 hours; peak about 0.7 to 2 hours [4][1]
  • Adverse events / fewer serious and non-serious events than comparators in a 2026 Cochrane review, low to very low certainty [3]
  • Compounding / FDA advisory committee voted 4 yes, 17 no in December 2024 [5]
  • Label cautions / pregnancy and breastfeeding, children, allergy or autoimmune disease, other immune-modulating drugs [1]

What the trials measured

The 2026 Cochrane review pooled 10 randomized trials with 1,349 adults who had chronic hepatitis B, published between 1991 and 2018. It looked at mortality, quality of life, liver histology, hepatitis B-related illness and adverse events, and the reviewers were not sure the drug helps [3]. Exercise capacity, strength, recovery and training tolerance are not among the outcomes reported.

A small 1991 placebo-controlled pilot gave 12 people with chronic hepatitis B thymosin fraction 5 or thymosin alpha-1 (7 people) or placebo (5) twice weekly for six months and reported no significant side effects in either group, but it did not assess exercise [6].

Safety data that bear on training

In the Cochrane review, thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious events (risk ratio 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [3].

FDA searched its adverse-event database on April 22, 2024 and found zero reports for thymosin alpha-1 [1]. Reports of infrequent and mild adverse experiences after marketing came from authors tied to its manufacturer, who describe more than 4,400 trial participants and more than 17 million doses given [1]. FDA still posts its compounding concerns for the peptide, including a significant risk of immunogenicity for certain routes of administration and safety information the agency called inadequate [7].

Anti-doping status

Thymosin alpha-1 is not named on WADA's 2026 Prohibited List [2]. The thymosin WADA does name is thymosin-beta-4 and its derivatives such as TB-500, under S2.3 (growth factors), a different peptide [2]. WADA's catch-all S0 class covers substances with no approval from any governmental health authority, and thymosin alpha-1 is approved in some countries [2][1].

Dosing and label cautions

There is no US-approved dose [1]. Italy's Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks from the first influenza vaccination, repeated from week 8 to week 12 at the second vaccination, in immunocompromised people [1]. That label says not for children, contraindicated in pregnancy and breastfeeding, and advises caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].

After a subcutaneous injection, blood levels peak at about 0.7 to 2 hours and clear with a half-life of about 1.8 to 2.6 hours, with no accumulation after daily dosing for five days [4][1].

Questions worth asking

Choose the questions you want to keep

Can I train on the day I inject thymosin alpha-1?
No study has established a training-day schedule. After a subcutaneous dose, blood levels peak at about 0.7 to 2 hours and the half-life is about 1.8 to 2.6 hours [4][1]. The Italian label's cautions are pregnancy and breastfeeding, children, allergy or autoimmune disease, and other immune-modulating drugs [1].
Will thymosin alpha-1 improve athletic performance?
Athletic performance, VO2 max and strength are not outcomes the 2026 Cochrane review assessed; it covered 10 trials and 1,349 adults with chronic hepatitis B and looked at outcomes such as mortality, quality of life, liver histology and adverse events [3]. Thymosin alpha-1 is described as an immune modulator that augments T-cell function [4].
Is thymosin alpha-1 a banned substance in sport?
It is not named on WADA's 2026 Prohibited List [2]. WADA does name thymosin-beta-4 and its derivatives such as TB-500 under S2.3, which is a different peptide [2].
Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US application, and its four orphan drug designations are not approvals [1]. It is authorized in Italy as an adjuvant to influenza vaccination in immunocompromised people, in India for chronic hepatitis B in adults 18 and older with compensated liver disease and virus replication, and in Hong Kong [1].
Show all 7 referencesHide references
  1. U.S. Food and Drug Administration.
  2. World Anti-Doping Agency.
  3. Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.
  4. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
  5. U.S. Food and Drug Administration.
  6. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991;14(3):409-15.
  7. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
Evidence overview for Thymosin Alpha-1 and Exercise: What to Know About Training While on This Medication